The global women’s health market size was valued at USD 32 billion in 2019 and is projected to expand at a CAGR of 4.9 % during the forecast period, 2021–2028. The growth of the market is attributed to the increasing geriatric women population, increasing lifestyle disorders, development of innovative medicines for women.
Menstrual cycles, pregnancy, birth control, and menopause are just a few of the health issues that women face. A number of health problems are unique to women, while others are more prevalent in women. Furthermore, males and women may have the same disease yet exhibit it different symptoms. Many diseases affect women differently and may need therapy that is tailored to their needs. Women’s health consists of treatments, drugs and surgical products for various diseases which affect women. Nutrition, cancer, reproduction, menopause, urology, and other medical applications are among these disorders. Women's health attempts to improve disease management and general health in women. Many governments are stepping up their efforts to raise awareness about women's health. Some institutions, such as the Food and Drug Administration (FDA) in the United States and the World Health Organization (WHO), are taking measures to develop new safety initiatives to enhance women's health. The FDA's primary aim, for example, is to improve the health of women across the world. Organizations are progressively focusing on enhancing security measures, recognizing security concerns, and boosting patient understanding to achieve these goals. The FDA has authorized numerous laser and energy devices for the treatment of a number of ailments, including the elimination of precancerous tissues of the cervix or vaginal region, as part of this approach. These initiatives increase awareness of women's health risks and stimulate the use of women's health services, resulting in increased growth in the worldwide women's health market. Women's fatality rates from breast cancer, cardiovascular disease, and cervical cancer have all decreased significantly in recent years. This is due to increased consumer demand and awareness, which has resulted in more investment and research, as well as improved diagnosis, screening, and treatment.
Market Trends, Drivers, Restraints, and Opportunities
- Increasing efforts by governments to spread awareness and favorable initiatives by governments to improve women’s health is projected to drive the market growth during the forecast period.
- Increasing incidence of diseases like osteoporosis, osteoarthritis, anemia, menstrual health-related disorders, depression, obesity, breast cancer, cardiovascular diseases, and mental diseases amongst women are anticipated to drive the market growth in the coming years.
- Side effects associated with some women intensive surgeries and drugs are projected to hamper the market growth in the coming years.
- High cost of some treatments is expected to restrict the market growth in the forecasted period.
- Increased emphasis on R&D for development of novel drugs, treatments, methods for diagnosis of various disorders are projected to offer lucrative opportunities for the market players.
Scope of the Report
The report on the global women’s health market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Women’s Health Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2020
|
|
Historic Data
|
2018–2019
|
|
Forecast Period
|
2021–2028
|
|
Segmentation
|
Application (Postmenopausal Osteoporosis, Hormonal Infertility, Endometriosis, Contraceptives, Menopause, Polycystic Ovary Syndrome)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Allergan; Bayer AG; Merck & Co., Inc.; Pfizer; Teva Pharmaceuticals; Agile Therapeutics; Amgen, Inc.; AstraZeneca; Bristol-Myers Squibb; and Ferring B.V.
|
Market Segment Insights
Postmenopausal osteoporosis segment is expected to account for a key share of the market
Based on application, the women’s health market is segmented into postmenopausal osteoporosis, hormonal infertility, endometriosis, contraceptives, menopause, polycystic ovary syndrome. The postmenopausal osteoporosis segment is expected to account for a key share of the market during the forecast period due to increasing population of women above 40 years and increasing number of product development cure menopausal osteoporosis and improve health.
On the other hand, the hormonal infertility segment is anticipated to expand at a rapid pace during the forecast period owing to increased fertility related issues in developed countries. Furthermore, the segment will grow due to the easy availability of several drugs to treat hormonal imbalances and market players' efforts in new product development throughout the forecast period. Hormonal imbalances, such as prolactin, estrogen, and thyroid imbalances, are becoming more common in women as a result of causes such as stress, fueling demand for medicine to restore health.
North America is anticipated to dominate the market
On the basis of regions, the women’s health market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market at an impressive CAGR during the forecast period. The regional market growth can be attributed to the presence of key market players, favorable reimbursement policies, favorable legislation, product approval and commercialization, and increased awareness of the value of good health. The market is also fueled by an increase in the number of FDA-approved menopause medicines, increasing healthcare expenditure, and women's preference for biologics.
On the other hand, Asia Pacific is expected to exhibit a rapid growth rate in the coming years owing to growing awareness of women's well-being and health, as well as an increase in the prevalence of osteoarthritis, infertility, and other stress-related problems, as well as numerous government initiatives aimed at raising women's health diagnostics and awareness.
Segments
Segments Covered in the Report
The global women’s health market has been segmented on the basis of
Application
- Postmenopausal Osteoporosis
- Hormonal Infertility
- Endometriosis
- Contraceptives
- Menopause
- Polycystic Ovary Syndrome (PCOS)
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Allergan
- Bayer AG
- Merck & Co., Inc.
- Pfizer
- Teva Pharmaceuticals
- Agile Therapeutics
- Amgen, Inc.
- AstraZeneca
- Bristol-Myers Squibb
- Ferring B.V.
Competitive Landscape
Key players competing in the women’s health market are Allergan; Bayer AG; Merck & Co., Inc.; Pfizer; Teva Pharmaceuticals; Agile Therapeutics; Amgen, Inc.; AstraZeneca; Bristol-Myers Squibb; and Ferring B.V.
Some of the key business strategies adopted by the key companies includes mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to increase their market shares. For instance,
For example, in September 2020, Health & Her, a female wellness company located in Cardiff, launched an app to assist women manage their menopausal journey, which includes workout recommendations, period monitoring, and symptom evaluation. Health & Her Perimenopause and Menopause Food Supplements is a new supplement line created by the firm.
Request For Customization
Enquiry Before Buying
Speak With Analyst
